JP2017512752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512752A5 JP2017512752A5 JP2016552268A JP2016552268A JP2017512752A5 JP 2017512752 A5 JP2017512752 A5 JP 2017512752A5 JP 2016552268 A JP2016552268 A JP 2016552268A JP 2016552268 A JP2016552268 A JP 2016552268A JP 2017512752 A5 JP2017512752 A5 JP 2017512752A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- solvate
- pharmaceutically acceptable
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CNC(*)C(NCC(*)NC([C@](CCC(O)=O)N[S+])=O)=O Chemical compound CNC(*)C(NCC(*)NC([C@](CCC(O)=O)N[S+])=O)=O 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940759P | 2014-02-17 | 2014-02-17 | |
| US61/940,759 | 2014-02-17 | ||
| US201461947368P | 2014-03-03 | 2014-03-03 | |
| US61/947,368 | 2014-03-03 | ||
| PCT/US2015/016185 WO2015123679A1 (en) | 2014-02-17 | 2015-02-17 | Hydrophilic antibody-drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020024690A Division JP2020073607A (ja) | 2014-02-17 | 2020-02-17 | 親水性抗体−薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017512752A JP2017512752A (ja) | 2017-05-25 |
| JP2017512752A5 true JP2017512752A5 (enExample) | 2018-01-25 |
| JP6716461B2 JP6716461B2 (ja) | 2020-07-01 |
Family
ID=53800705
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552268A Expired - Fee Related JP6716461B2 (ja) | 2014-02-17 | 2015-02-17 | 親水性抗体−薬物コンジュゲート |
| JP2020024690A Withdrawn JP2020073607A (ja) | 2014-02-17 | 2020-02-17 | 親水性抗体−薬物コンジュゲート |
| JP2022078761A Active JP7447183B2 (ja) | 2014-02-17 | 2022-05-12 | 親水性抗体－薬物コンジュゲート |
| JP2022194229A Pending JP2023018157A (ja) | 2014-02-17 | 2022-12-05 | 親水性抗体－薬物コンジュゲート |
| JP2024075020A Pending JP2024096335A (ja) | 2014-02-17 | 2024-05-06 | 親水性抗体－薬物コンジュゲート |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020024690A Withdrawn JP2020073607A (ja) | 2014-02-17 | 2020-02-17 | 親水性抗体−薬物コンジュゲート |
| JP2022078761A Active JP7447183B2 (ja) | 2014-02-17 | 2022-05-12 | 親水性抗体－薬物コンジュゲート |
| JP2022194229A Pending JP2023018157A (ja) | 2014-02-17 | 2022-12-05 | 親水性抗体－薬物コンジュゲート |
| JP2024075020A Pending JP2024096335A (ja) | 2014-02-17 | 2024-05-06 | 親水性抗体－薬物コンジュゲート |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10933112B2 (enExample) |
| EP (2) | EP3912641B1 (enExample) |
| JP (5) | JP6716461B2 (enExample) |
| KR (3) | KR20240036143A (enExample) |
| CN (1) | CN106029083B (enExample) |
| AU (3) | AU2015218202B2 (enExample) |
| CA (1) | CA2937753A1 (enExample) |
| EA (1) | EA201691650A1 (enExample) |
| ES (2) | ES2885686T3 (enExample) |
| IL (4) | IL309933A (enExample) |
| MX (2) | MX385823B (enExample) |
| SG (2) | SG10202001468UA (enExample) |
| WO (1) | WO2015123679A1 (enExample) |
| ZA (1) | ZA201605111B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2937753A1 (en) * | 2014-02-17 | 2015-08-20 | Seattle Genetics, Inc. | Hydrophilic antibody-drug conjugates |
| CN107029242A (zh) | 2015-11-03 | 2017-08-11 | 财团法人工业技术研究院 | 抗体药物复合物及其制造方法 |
| TWI851531B (zh) | 2016-08-09 | 2024-08-11 | 美商思進公司 | 具有改善之生理化學性質之具自我穩定連接子之藥物結合物 |
| US11419944B2 (en) | 2016-10-11 | 2022-08-23 | Byondis B.V. | Non-linear self-immolative linkers and conjugates thereof |
| CN110177805B (zh) | 2016-10-19 | 2024-04-02 | 英温拉公司 | 抗体构建体 |
| AU2017383142A1 (en) | 2016-12-22 | 2019-07-04 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43 |
| MX2019011635A (es) | 2017-03-30 | 2020-01-20 | Jiangsu Hengrui Medicine Co | Método para la preparación de conjugados anticuerpo-fármaco. |
| US12605458B2 (en) | 2017-06-19 | 2026-04-21 | Systimmune, Inc. | Antibody-drug conjugate having acidic self-stabilization junction |
| WO2019034176A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| WO2019034177A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
| WO2019096867A1 (en) | 2017-11-14 | 2019-05-23 | Debiopharm Research & Manufacturing S.A. | Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of cathepsin b |
| SG11202007540SA (en) | 2018-02-20 | 2020-09-29 | Seattle Genetics Inc | Hydrophobic auristatin f compounds and conjugates thereof |
| CN120795120A (zh) | 2018-06-05 | 2025-10-17 | 伦敦大学国王学院 | 向胃肠系统递送酬载的btnl3/8导引构建体 |
| CN114728073B (zh) * | 2019-09-19 | 2024-12-27 | 思进股份有限公司 | 药物从生物活性化合物的内化缀合物的选择性释放 |
| WO2021180969A1 (en) | 2020-03-12 | 2021-09-16 | Technische Universität München | Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| US20240209080A1 (en) | 2021-04-10 | 2024-06-27 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| CN118119409A (zh) | 2021-09-03 | 2024-05-31 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| WO2023083381A1 (zh) | 2021-11-15 | 2023-05-19 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-喜树碱类药物偶联物及其医药用途 |
| WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
| WO2023098889A1 (zh) * | 2021-12-03 | 2023-06-08 | 成都百利多特生物药业有限责任公司 | 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途 |
| CN119317646A (zh) * | 2022-06-16 | 2025-01-14 | 山东博安生物技术股份有限公司 | 抗liv-1抗体及其药物偶联物 |
| EP4548932A1 (en) | 2022-06-30 | 2025-05-07 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| CN121793988A (zh) | 2023-09-13 | 2026-04-03 | 东丽株式会社 | 癌的治疗、预防和/或诊断用药物组合物 |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| US20250381289A1 (en) | 2024-02-29 | 2025-12-18 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2026007511A1 (en) * | 2024-07-05 | 2026-01-08 | Beijing Innocare Pharma Tech Co., Ltd. | Drug conjugates, their preparation methods and uses |
| WO2026027771A1 (en) | 2024-08-02 | 2026-02-05 | Trimt Gmbh | Alpha v beta 6-integrin binding cyclopeptides with non-natural amino acids, and conjugates thereof |
| US20260048137A1 (en) | 2024-08-16 | 2026-02-19 | Ardeagen Corporation | Anti-mesothelin antibody conjugates and methods of use thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3628624A (en) | 1967-04-26 | 1971-12-21 | Buero Patent Ag | Guidance system for self-propelled trackless carriages |
| GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| JP2001505194A (ja) * | 1996-11-05 | 2001-04-17 | ブリストル―マイヤーズ・スクイブ・カンパニー | 分枝ペプチド・リンカー |
| DK1545613T3 (da) * | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| JP5122441B2 (ja) | 2005-04-19 | 2013-01-16 | シアトル ジェネティックス， インコーポレイテッド | ヒト化抗ｃｄ７０結合剤およびその使用 |
| ES2708763T3 (es) * | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| WO2007086083A1 (en) | 2006-01-24 | 2007-08-02 | Tecnoimage Srl | Supporting frame for covering elements |
| US8257706B2 (en) | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
| AR065404A1 (es) | 2007-02-21 | 2009-06-03 | Medarex Inc | Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| DK2265283T3 (da) * | 2008-03-18 | 2014-10-20 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| EP2648752B1 (en) | 2010-12-06 | 2017-02-15 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| SG11201404354UA (en) | 2012-02-17 | 2014-10-30 | Seattle Genetics Inc | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER |
| EP2832856A4 (en) | 2012-03-29 | 2016-01-27 | Chugai Pharmaceutical Co Ltd | ANTI-LAMP5 ANTIBODIES AND USE THEREOF |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| CA2937753A1 (en) | 2014-02-17 | 2015-08-20 | Seattle Genetics, Inc. | Hydrophilic antibody-drug conjugates |
| CN114728073B (zh) | 2019-09-19 | 2024-12-27 | 思进股份有限公司 | 药物从生物活性化合物的内化缀合物的选择性释放 |
| CA3213625A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
-
2015
- 2015-02-17 CA CA2937753A patent/CA2937753A1/en active Pending
- 2015-02-17 ES ES15748980T patent/ES2885686T3/es active Active
- 2015-02-17 KR KR1020247007857A patent/KR20240036143A/ko not_active Withdrawn
- 2015-02-17 SG SG10202001468UA patent/SG10202001468UA/en unknown
- 2015-02-17 EA EA201691650A patent/EA201691650A1/ru unknown
- 2015-02-17 IL IL309933A patent/IL309933A/en unknown
- 2015-02-17 SG SG11201605886RA patent/SG11201605886RA/en unknown
- 2015-02-17 EP EP21168364.4A patent/EP3912641B1/en active Active
- 2015-02-17 AU AU2015218202A patent/AU2015218202B2/en not_active Ceased
- 2015-02-17 ES ES21168364T patent/ES2994375T3/es active Active
- 2015-02-17 KR KR1020167025612A patent/KR20160120777A/ko not_active Ceased
- 2015-02-17 KR KR1020237014278A patent/KR102647074B1/ko active Active
- 2015-02-17 EP EP15748980.8A patent/EP3107557B1/en active Active
- 2015-02-17 MX MX2016009862A patent/MX385823B/es unknown
- 2015-02-17 US US15/118,031 patent/US10933112B2/en active Active
- 2015-02-17 IL IL290116A patent/IL290116B2/en unknown
- 2015-02-17 JP JP2016552268A patent/JP6716461B2/ja not_active Expired - Fee Related
- 2015-02-17 CN CN201580008876.3A patent/CN106029083B/zh not_active Expired - Fee Related
- 2015-02-17 WO PCT/US2015/016185 patent/WO2015123679A1/en not_active Ceased
-
2016
- 2016-07-19 IL IL246829A patent/IL246829B/en active IP Right Grant
- 2016-07-21 ZA ZA2016/05111A patent/ZA201605111B/en unknown
- 2016-07-28 MX MX2021010550A patent/MX2021010550A/es unknown
-
2020
- 2020-02-17 JP JP2020024690A patent/JP2020073607A/ja not_active Withdrawn
- 2020-09-24 AU AU2020239744A patent/AU2020239744B2/en not_active Ceased
-
2021
- 2021-01-27 US US17/160,225 patent/US11510959B2/en active Active
- 2021-04-19 IL IL282434A patent/IL282434B/en unknown
-
2022
- 2022-05-12 JP JP2022078761A patent/JP7447183B2/ja active Active
- 2022-10-11 US US17/963,939 patent/US20230132738A1/en not_active Abandoned
- 2022-12-05 JP JP2022194229A patent/JP2023018157A/ja active Pending
-
2023
- 2023-03-06 AU AU2023201373A patent/AU2023201373A1/en not_active Abandoned
- 2023-07-28 US US18/361,558 patent/US12257281B2/en active Active
-
2024
- 2024-05-06 JP JP2024075020A patent/JP2024096335A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512752A5 (enExample) | ||
| RU2451029C2 (ru) | Производное инсулина | |
| CN103442736B (zh) | 具有改良键合的鹅膏毒素共轭物 | |
| JP2023018157A (ja) | 親水性抗体－薬物コンジュゲート | |
| JP2014516993A5 (enExample) | ||
| JP2013505944A5 (enExample) | ||
| JP2021100937A5 (enExample) | ||
| JP2017537893A5 (enExample) | ||
| RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
| JP2015527318A5 (enExample) | ||
| JP2020510662A5 (enExample) | ||
| JP2017518304A5 (enExample) | ||
| JP2010521485A5 (enExample) | ||
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| KR970042553A (ko) | 캠프토테신 유도체 | |
| NZ745069A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| JP2011500725A5 (enExample) | ||
| RU2014128467A (ru) | Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение | |
| RU2015119561A (ru) | Новые конъюгаты лекарственное вещество-белок | |
| JP2014528466A5 (enExample) | ||
| RU2011118055A (ru) | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств | |
| JPWO2008010463A1 (ja) | コンブレタスタチン類の高分子結合体 | |
| BRPI0807232A2 (pt) | Tratamento de cânceres resistentes ou refratários com conjugados poliméricos multi-braços de 7-etil-10-hidroxicamptotecina | |
| FI3065763T4 (fi) | Il-22-dimeerin käyttö lääkkeen valmistamisessa suonensisäistä antoa varten | |
| JP2025186263A (ja) | Ｅｐｉ－ｘ４系ペプチドおよびその誘導体 |